Authors

Talal Hilal, MD

Latest:

Addressing a Crisis of Authorship Abuse

Talal Hilal, MD, on the ethical principles of medical authorship and a just distribution of credit.

Talia Golan, MD

Latest:

Dr. Golan on the Phase III POLO Trial in BRCA-Mutant Pancreatic Cancer

Talia Golan, MD, head of Sheba Pancreatic Cancer Center, discusses the results of the phase III POLO trial, which evaluated maintenance olaparib compared with placebo among patients with germline BRCA-mutated metastatic pancreatic cancer.

Tami L. Thomas, PhD, CPNP, RNC, FAANP

Latest:

Promoting HPV Vaccination for Girls and Boys

Oncology nurses can lead the way in efforts to protect the next generation from this type of cancer if they know the facts about HPV vaccination for both girls and boys

Tanguy I. Seiwert, MD

Latest:

Dr. Seiwert on Managing Side Effects for Head and Neck Cancer Treatment

Tanguy I. Seiwert, MD, assistant professor of Medicine, University of Chicago Medicine, discusses managing toxicities associated with immunotherapy for patients with head and neck cancer.

Tanguy Seiwert, MD

Latest:

Dr. Seiwert on Final Thoughts on Immunotherapy in Head and Neck Cancer

Tanguy I. Seiwert, MD, assistant professor of Medicine, University of Chicago Medicine, discusses some final opinions on immunotherapy agents in the landscape of head and neck cancer.

Tanguy Sewiert, MD

Latest:

Dr. Seiwert on Pembrolizumab in Head and Neck Cancer

Tanguy Seiwert, MD, assistant professor of medicine and associate leader of the head and neck cancer program, University of Chicago, discusses the efficacy of pembrolizumab in head and neck cancer.

Tanguy Y. Seiwert, MD

Latest:

Dr. Seiwert on Immunotherapy in Head and Neck Cancer

Tanguy Y. Seiwert, MD, assistant professor of Medicine, University of Chicago Medicine, discusses the impact of immunotherapy agents as treatment of patients with head and neck cancer.

Tanguy Y. Seiwert, MD, The University of Chicago Medical Center

Tania Jain, MBBS

Latest:

Dr Jain on Baseline Differences Across Different Donor Types in Myelofibrosis

Tania Jain, MBBS, discusses notable differences in baseline characteristics and donor sequencing, according to a retrospective study of patient outcomes following blood or marrow transplant in 4 common donor types of myelofibrosis.

Tanio

Tanios

Tanios Bekaii-Saab, MD

Latest:

Dr Bekaii-Saab on the Future of Treatment For Patients With GI Cancer

Tanios Bekaii-Saab, MD, FACP, discusses the future of treatment within the gastrointestinal cancers armamentarium.

Tanios Bekaii-Saab, MD, FACP

Latest:

Dr Bekaii-Saab on the RATIONALE-306 Study of Tislelizumab Plus Chemotherapy in Esophageal Cancer

Tanios S. Bekaii-Saab, MD, FACP, discusses the use of tislelizumab plus chemotherapy in unresectable or metastatic ESCC.

Tanios Bekaii-Saab, MD, FACP, Mayo Clinic

Latest:

Audience Q&A: Best Practices in Managing HER2-Amplified CRC

Fielding questions from the audience, expert oncologists discuss clinical trials, molecular testing, and early-stage disease in the context of HER2-amplified colorectal cancer.

Tanios Bekaii-Saab, MD, Mayo Clinic

Latest:

Exciting Treatment Opportunities in mCRC

Closing out a discussion on novel therapies used to individualize treatment for patients with metastatic colorectal cancer, a panel of gastrointestinal oncologists highlight the most exciting treatment opportunities being explored to address current gaps in care.

Tanios Bekaii-Saab, MD, Mayo Clinic Cancer Center in Arizona

Tanios Bekaii-Saab, MD, Ohio State University-James Cancer Hospital

Tanios Bekaii-Saab, MD, OSUCCC

Tanios Bekaii-Saab, MD, The Mayo Clinic

Tanios S